deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT04730258

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML (TWT-202)

Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine in Patients With AML, MDS or CMML

Sponsor: Treadwell Therapeutics, Inc

Conditions AML Acute Myeloid Leukemia CMML Chronic Myelomonocytic Leukemia MDS Myelodysplastic Syndromes
Interventions Azacitidine CFI-400945
Updated 15 times since 2021 Last updated: May 16, 2025 Started: Apr 16, 2021 Primary completion: Jan 31, 2026 Completion: Jan 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04730258, this PHASE1/PHASE2 trial focuses on AML and Acute Myeloid Leukemia and remains ongoing. Sponsored by Treadwell Therapeutics, Inc, it has been updated 15 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshot~Mar 2023 – ~Aug 2023 · 5 months · monthly snapshot~Aug 2023 – ~Dec 2023 · 4 months · monthly snapshot~Dec 2023 – ~Mar 2024 · 3 months · monthly snapshot~Mar 2024 – ~May 2024 · 2 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jun 2025 · 8 months · monthly snapshot~Jun 2025 – present · 14 months · monthly snapshot

Change History

15 versions recorded

  1. Jun 2025 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Oct 2024 — Jun 2025 [monthly]

    Recruiting PHASE1/PHASE2

  3. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. May 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 10 earlier versions

  1. Mar 2024 — May 2024 [monthly]

    Recruiting PHASE1_PHASE2

  2. Dec 2023 — Mar 2024 [monthly]

    Recruiting PHASE1_PHASE2

  3. Aug 2023 — Dec 2023 [monthly]

    Recruiting PHASE1_PHASE2

  4. Mar 2023 — Aug 2023 [monthly]

    Recruiting PHASE1_PHASE2

  5. Sep 2022 — Mar 2023 [monthly]

    Recruiting PHASE1_PHASE2

  6. Sep 2021 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Jun 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  8. May 2021 — Jun 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  9. Apr 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  10. Feb 2021 — Apr 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Treadwell Therapeutics, Inc
Data source: Treadwell Therapeutics, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations